SEC Form 4 · accession 0001104659-17-004702
Syros Pharmaceuticals, Inc. · SYRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Wirth
Director
Period of report
Jan 27, 2017
Accepted (ET)
Jan 30, 2017 · 8:42 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001556263
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $10.76 | Jan 27, 2017 | A | 22,000 | A | — | Jan 26, 2027 | Common Stock | 22,000 | 22,000 | D |
Explanation of responses
- F1The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the third anniversary of the date of the award, subject to Mr. Wirth's continued service as a director through each applicable vesting date.